Bendamustine plus rituximab: is it a BRIGHT idea? | Zendy

Carlo Visco | Zendy; Francesca Maria Quaglia | Zendy; Chiara Bovo | Zendy; Maria Chiara Tisi | Zendy; Mauro Krampera | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Bendamustine plus rituximab: is it a BRIGHT idea?

Author(s) -

Carlo Visco,

Francesca Maria Quaglia,

Chiara Bovo,

Maria Chiara Tisi,

Mauro Krampera

Publication year - 2019

Publication title -

chinese clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.733

H-Index - 22

eISSN - 2304-3873

pISSN - 2304-3865

DOI - 10.21037/cco.2019.10.03

Subject(s) - medicine , rituximab , bendamustine , prednisone , vincristine , mantle cell lymphoma , cyclophosphamide , chop , lymphoma , oncology , chemotherapy

Flinn et al . have reported the results of the long-term follow-up for the BRIGHT trial, an international study which compared the efficacy and the safety of bendamustine plus rituximab (BR) with either rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or rituximab plus cyclophosphamide, vincristine, and prednisone (R-CVP) for treatment-naive patients with indolent non-Hodgkin lymphoma (iNHL) or mantle-cell lymphoma (MCL).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research